[Multicenter study of the clinical efficacy and tolerance of roxithromicin compared to doxycycline in lower respiratory infections].
J Charpin, P Fréour, J Marsac
Abstract
J Charpin, P Fréour, J Marsac
Abstract
In a double-blind, randomised investigation in 305 in-patients, roxithromycin and doxycycline were compared in two groups of patients with low respiratory tract infections. Three hundred cases were analyzable for safety and 276 for clinical efficacy. Mean duration of treatment was 9 days in both groups. Clinical effectiveness was 83% (112/135) for roxithromycin (150 mg bd) and 84% (118/141) for doxycycline (200 mg once daily), the difference not being statistically significant. A 90% clinical response rate was obtained with roxithromycin in pneumoniae. Safety and tolerance were good and comparable in both groups.
OpenAlex reports 4 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
In a double-blind, randomised investigation in 305 in-patients, roxithromycin and doxycycline were compared in two groups of patients with low respiratory tract infections. Three hundred cases were analyzable for safety and 276 for clinical efficacy. Mean duration of treatment was 9 days in both groups. Clinical effectiveness was 83% (112/135) for roxithromycin (150 mg bd) and 84% (118/141) for doxycycline (200 mg once daily), the difference not being statistically significant. A 90% clinical response rate was obtained with roxithromycin in pneumoniae. Safety and tolerance were good and comparable in both groups.
Key concepts: Roxithromycin, Doxycycline, Medicine, Internal medicine, Clinical efficacy, Respiratory tract infections, Clinical trial, Gastroenterology